343 related articles for article (PubMed ID: 26429982)
1. Targeting of HPV-16+ Epithelial Cancer Cells by TCR Gene Engineered T Cells Directed against E6.
Draper LM; Kwong ML; Gros A; Stevanović S; Tran E; Kerkar S; Raffeld M; Rosenberg SA; Hinrichs CS
Clin Cancer Res; 2015 Oct; 21(19):4431-9. PubMed ID: 26429982
[TBL] [Abstract][Full Text] [Related]
2. A conserved E7-derived cytotoxic T lymphocyte epitope expressed on human papillomavirus 16-transformed HLA-A2+ epithelial cancers.
Riemer AB; Keskin DB; Zhang G; Handley M; Anderson KS; Brusic V; Reinhold B; Reinherz EL
J Biol Chem; 2010 Sep; 285(38):29608-22. PubMed ID: 20615877
[TBL] [Abstract][Full Text] [Related]
3. Identification of an HLA-A24-restricted cytotoxic T lymphocyte epitope from human papillomavirus type-16 E6: the combined effects of bortezomib and interferon-gamma on the presentation of a cryptic epitope.
Morishima S; Akatsuka Y; Nawa A; Kondo E; Kiyono T; Torikai H; Nakanishi T; Ito Y; Tsujimura K; Iwata K; Ito K; Kodera Y; Morishima Y; Kuzushima K; Takahashi T
Int J Cancer; 2007 Feb; 120(3):594-604. PubMed ID: 17096336
[TBL] [Abstract][Full Text] [Related]
4. Identification of a naturally processed HLA-A*0201 HPV18 E7 T cell epitope by tumor cell mediated in vitro vaccination.
Kather A; Ferrara A; Nonn M; Schinz M; Nieland J; Schneider A; Dürst M; Kaufmann AM
Int J Cancer; 2003 Apr; 104(3):345-53. PubMed ID: 12569558
[TBL] [Abstract][Full Text] [Related]
5. HLA-A2-restricted peripheral blood cytolytic T lymphocyte response to HPV type 16 proteins E6 and E7 from patients with neoplastic cervical lesions.
Evans C; Bauer S; Grubert T; Brucker C; Baur S; Heeg K; Wagner H; Lipford GB
Cancer Immunol Immunother; 1996 Mar; 42(3):151-60. PubMed ID: 8640843
[TBL] [Abstract][Full Text] [Related]
6. HPV-16 E6 and E7 protein T cell epitopes prediction analysis based on distributions of HLA-A loci across populations: an in silico approach.
Yao Y; Huang W; Yang X; Sun W; Liu X; Cun W; Ma Y
Vaccine; 2013 Apr; 31(18):2289-94. PubMed ID: 23499609
[TBL] [Abstract][Full Text] [Related]
7. Identification and characterization of enhancer agonist human cytotoxic T-cell epitopes of the human papillomavirus type 16 (HPV16) E6/E7.
Tsang KY; Fantini M; Fernando RI; Palena C; David JM; Hodge JW; Gabitzsch ES; Jones FR; Schlom J
Vaccine; 2017 May; 35(19):2605-2611. PubMed ID: 28389098
[TBL] [Abstract][Full Text] [Related]
8. Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes for adoptive immunotherapy of HPV-associated malignancies.
Ramos CA; Narala N; Vyas GM; Leen AM; Gerdemann U; Sturgis EM; Anderson ML; Savoldo B; Heslop HE; Brenner MK; Rooney CM
J Immunother; 2013 Jan; 36(1):66-76. PubMed ID: 23211628
[TBL] [Abstract][Full Text] [Related]
9. Human papillomavirus 16-specific T cell responses in classic HPV-related vulvar intra-epithelial neoplasia. Determination of strongly immunogenic regions from E6 and E7 proteins.
Bourgault Villada I; Moyal Barracco M; Berville S; Bafounta ML; Longvert C; Prémel V; Villefroy P; Jullian E; Clerici T; Paniel B; Maillère B; Choppin J; Guillet JG
Clin Exp Immunol; 2010 Jan; 159(1):45-56. PubMed ID: 19843089
[TBL] [Abstract][Full Text] [Related]
10. Recognition of a cervical cancer derived tumor cell line by a human papillomavirus type 16 E6 52-61-specific CD8 T cell clone.
Kim KH; Dishongh R; Santin AD; Cannon MJ; Bellone S; Nakagawa M
Cancer Immun; 2006 Jun; 6():9. PubMed ID: 16808432
[TBL] [Abstract][Full Text] [Related]
11. Human papillomavirus type 16 E7 peptide-directed CD8+ T cells from patients with cervical cancer are cross-reactive with the coronavirus NS2 protein.
Nilges K; Höhn H; Pilch H; Neukirch C; Freitag K; Talbot PJ; Maeurer MJ
J Virol; 2003 May; 77(9):5464-74. PubMed ID: 12692247
[TBL] [Abstract][Full Text] [Related]
12. Dual T cell receptor/chimeric antigen receptor engineered NK-92 cells targeting the HPV16 E6 oncoprotein and the tumor-associated antigen L1CAM exhibit enhanced cytotoxicity and specificity against tumor cells.
Quiros-Fernandez I; Libório-Ramos S; Leifert L; Schönfelder B; Vlodavsky I; Cid-Arregui A
J Med Virol; 2024 May; 96(5):e29630. PubMed ID: 38659368
[TBL] [Abstract][Full Text] [Related]
13. Human papillomavirus 16 E6-specific CD45RA+ CCR7+ high avidity CD8+ T cells fail to control tumor growth despite interferon-gamma production in patients with cervical cancer.
Zehbe I; Kaufmann AM; Schmidt M; Hohn H; Maeurer MJ
J Immunother; 2007; 30(5):523-32. PubMed ID: 17589293
[TBL] [Abstract][Full Text] [Related]
14. Generating HPV specific T helper cells for the treatment of HPV induced malignancies using TCR gene transfer.
Scholten KB; Turksma AW; Ruizendaal JJ; van den Hende M; van der Burg SH; Heemskerk MH; Meijer CJ; Hooijberg E
J Transl Med; 2011 Sep; 9():147. PubMed ID: 21892941
[TBL] [Abstract][Full Text] [Related]
15. Identification of the impact on T- and B- cell epitopes of human papillomavirus type-16 E6 and E7 variant in Southwest China.
Chenzhang Y; Wen Q; Ding X; Cao M; Chen Z; Mu X; Wang T
Immunol Lett; 2017 Jan; 181():26-30. PubMed ID: 27693214
[TBL] [Abstract][Full Text] [Related]
16. Customized Viral Immunotherapy for HPV-Associated Cancer.
Atherton MJ; Stephenson KB; Pol J; Wang F; Lefebvre C; Stojdl DF; Nikota JK; Dvorkin-Gheva A; Nguyen A; Chen L; Johnson-Obaseki S; Villeneuve PJ; Diallo JS; Dimitroulakos J; Wan Y; Lichty BD
Cancer Immunol Res; 2017 Oct; 5(10):847-859. PubMed ID: 28912369
[TBL] [Abstract][Full Text] [Related]
17. Dendritic cell-based tumor vaccine for cervical cancer I: in vitro stimulation with recombinant protein-pulsed dendritic cells induces specific T cells to HPV16 E7 or HPV18 E7.
Nonn M; Schinz M; Zumbach K; Pawlita M; Schneider A; Dürst M; Kaufmann AM
J Cancer Res Clin Oncol; 2003 Sep; 129(9):511-20. PubMed ID: 12905010
[TBL] [Abstract][Full Text] [Related]
18. Combination Vaccination With Tetanus Toxoid and Enhanced Tumor-Cell Based Vaccine Against Cervical Cancer in a Mouse Model.
Alson D; Schuyler SC; Yan BX; Samimuthu K; Qiu JT
Front Immunol; 2020; 11():927. PubMed ID: 32547541
[TBL] [Abstract][Full Text] [Related]
19. Enhanced Cytotoxic CD8 T Cell Priming Using Dendritic Cell-Expressing Human Papillomavirus-16 E6/E7-p16INK4 Fusion Protein with Sequenced Anti-Programmed Death-1.
Garcia-Bates TM; Kim E; Concha-Benavente F; Trivedi S; Mailliard RB; Gambotto A; Ferris RL
J Immunol; 2016 Mar; 196(6):2870-8. PubMed ID: 26851223
[TBL] [Abstract][Full Text] [Related]
20. Memory T cells specific for novel human papillomavirus type 16 (HPV16) E6 epitopes in women whose HPV16 infection has become undetectable.
Wang X; Moscicki AB; Tsang L; Brockman A; Nakagawa M
Clin Vaccine Immunol; 2008 Jun; 15(6):937-45. PubMed ID: 18448624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
